Live Breaking News & Updates on Iolinerx ltd quot biolinerx nasdaq tase blrx

NEW YORK, June 29, 2022 /PRNewswire/ M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc., an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC"). Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China. This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. "This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, wh ....

China , Shanghai , Philip-serlin , Qiang-lu , Genfleet-therapeutics-inc , Biolinerx-ltd , Genfleet-therapeutics , New-york , June-29 , 022-prnewswirem-sq-ventures-quot-msq-is-pleased-to-announce-that-its-client , Iolinerx-ltd-quot-biolinerx-nasdaq-tase-blrx- , As-successfully-entered-intoa-co-development-agreement-with-genfleet-therapeutics